Biogen is an American biotech company based in Cambridge, Massachusetts. The company uses recombinant DNA technology, also known as biotechnology. This makes it possible to produce human proteins and therefore medicinal products with the help of microorganisms. The company continues to develop new substances and works on improving already approved molecules.
As of March 2025 Biogen has a market cap of โฌ19.18 Billion. This makes Biogen the world's 966th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Year | Marketcap | Change |
---|---|---|
2025 | โฌ19.18 B | -9.47% |
2024 | โฌ21.18 B | -37.53% |
2023 | โฌ33.91 B | -8.76% |
2022 | โฌ37.17 B | 19.46% |
2021 | โฌ31.11 B | 1.58% |
2020 | โฌ30.63 B | -33.61% |
2019 | โฌ46.14 B | -11.05% |
2018 | โฌ51.87 B | -7.62% |
2017 | โฌ56.14 B | -4.28% |
2016 | โฌ58.65 B | -4.23% |
2015 | โฌ61.24 B | -6.45% |
2014 | โฌ65.46 B | 36.84% |
2013 | โฌ47.84 B | 82.76% |
2012 | โฌ26.17 B | 27.17% |
2011 | โฌ20.58 B | 69.77% |
2010 | โฌ12.12 B | 18.14% |
2009 | โฌ10.26 B | 4.58% |
2008 | โฌ9.81 B | -14.86% |
2007 | โฌ11.52 B | -8.28% |
2006 | โฌ12.56 B | -3.13% |
2005 | โฌ12.97 B | -22.24% |
2004 | โฌ16.68 B |
On Mar 24th, 2025 the market cap of Biogen was reported to be: